Literature DB >> 6966398

Role of the degradation process in the mitogenic effect of epidermal growth factor.

N Savion, I Vlodavsky, D Gospodarowicz.   

Abstract

The protease inhibitor leupeptin inhibits the degradation process of (125)I-labeled epidermal growth factor ((125)I-EGF) by cultured bovine granulosa cells. At 80 mug/ml, leupeptin inhibited the appearance of degradation products of (125)I-EGF in the medium by 95% during 1 hr of incubation and by 90% during 24 hr of incubation when the cells were exposed to 5 ng of (125)I-EGF per ml. In contrast, cultures exposed to either saturating (10 ng/ml) or nonsaturating (0.1 ng/ml) concentrations of EGF in the presence of leupeptin (80 mug/ml) exhibited an increase in DNA synthesis that was 70-80% that of cultures exposed to EGF alone. Cultures responded to either EGF or fibroblast growth factor with a logarithmic increase in cell number and, over a period of 8 days, the number of cells increased 10- to 18-fold. Addition of leupeptin did not diminish the growth rate of the cultures. In the presence of leupeptin, (125)I-EGF accumulated within the granulosa cells and was in a form that was precipitable with antiserum against EGF and that comigrated on isoelectric focusing with native (125)I-EGF. That a full mitogenic response can be obtained despite a 90-95% inhibition of EGF degradation at either saturating or nonsaturating concentrations of the mitogen suggests that a proteolytic degradation of a given mitogen may not be involved in the induction of a proliferative response.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6966398      PMCID: PMC348516          DOI: 10.1073/pnas.77.3.1466

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

2.  Structures and activities of protease inhibitors of microbial origin.

Authors:  H Umezawa
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

3.  Epidermal growth factor: biological activity requires persistent occupation of high-affinity cell surface receptors.

Authors:  Y Shechter; L Hernaez; P Cuatrecasas
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

4.  Epidermal growth factor and a new derivative. Rapid isolation procedures and biological and chemical characterization.

Authors:  C R Savage; S Cohen
Journal:  J Biol Chem       Date:  1972-12-10       Impact factor: 5.157

5.  Molecular mechanism of mitogen action: processing of receptor induced by epidermal growth factor.

Authors:  M Das; C F Fox
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

6.  The effects of the epidermal and fibroblast growth factors on the replicative lifespan of cultured bovine granulosa cells.

Authors:  D Gospodarowicz; H Bialecki
Journal:  Endocrinology       Date:  1978-09       Impact factor: 4.736

7.  Local aggregation of hormone-receptor complexes is required for activation by epidermal growth factor.

Authors:  Y Schechter; L Hernaez; J Schlessinger; P Cuatrecasas
Journal:  Nature       Date:  1979-04-26       Impact factor: 49.962

Review 8.  Receptor-mediated endocytosis: insights from the lipoprotein receptor system.

Authors:  M S Brown; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

9.  Direct visualization of the binding and internalization of a ferritin conjugate of epidermal growth factor in human carcinoma cells A-431.

Authors:  H T Haigler; J A McKanna; S Cohen
Journal:  J Cell Biol       Date:  1979-05       Impact factor: 10.539

10.  125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts.

Authors:  G Carpenter; S Cohen
Journal:  J Cell Biol       Date:  1976-10       Impact factor: 10.539

View more
  9 in total

1.  Interaction between monensin and lysosomotropic amines in the regulation of the processing of epidermal growth factor by BALB/c 3T3 cells.

Authors:  J L Cooper; R Selinfreund; E Wakshull; W Wharton
Journal:  Mol Cell Biochem       Date:  1987-01       Impact factor: 3.396

2.  Genetics of cell surface receptors for bioactive polypeptides: variants of Swiss/3T3 fibroblasts resistant to a cytotoxic chimeric insulin.

Authors:  W K Miskimins; N Shimizu
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

Review 3.  Epidermal growth factor receptors.

Authors:  E D Adamson; A R Rees
Journal:  Mol Cell Biochem       Date:  1981-02-11       Impact factor: 3.396

4.  Intracellular Ca2+ and phorbol esters synergistically inhibit internalization of epidermal growth factor in pancreatic acini.

Authors:  C D Logsdon; J A Williams
Journal:  Biochem J       Date:  1984-11-01       Impact factor: 3.857

5.  Stimulation of DNA synthesis by epidermal growth factor in osteoblast-like cells.

Authors:  K W Ng; N C Partridge; M Niall; T J Martin
Journal:  Calcif Tissue Int       Date:  1983-07       Impact factor: 4.333

6.  Lysosomotropic amines inhibit mitogenesis induced by growth factors.

Authors:  A C King; L Hernaez-Davis; P Cuatrecasas
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

7.  Epidermal growth factor stimulation of ornithine decarboxylase activity in a human hepatoma cell line.

Authors:  D M Moriarity; D M DiSorbo; G Litwack; C R Savage
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

8.  Murine epidermal growth factor: heterogeneity on high resolution ion-exchange chromatography.

Authors:  A W Burgess; C J Lloyd; E C Nice
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

9.  A nonmitogenic analogue of epidermal growth factor induces early responses mediated by epidermal growth factor.

Authors:  Y Yarden; A B Schreiber; J Schlessinger
Journal:  J Cell Biol       Date:  1982-03       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.